Desai RJ, et al. - In this observational cohort study, researchers assessed the risk of venous thromboembolism (VTE) in rheumatoid arthritis (RA) patients receiving tofacitinib compared to those receiving tumor necrosis factor (TNF) inhibitors. The Truven and Medicare databases identified a total of 34,074 RA patients and 17,086 RA patients respectively. Findings revealed that there was an infrequent occurrence of VTE in a total of 50,865 RA patients initiating tofacitinib treatment or an inhibitor of TNF. In RA patients receiving tofacitinib vs those receiving TNF inhibitors, they noted a numerically higher, but statistically non-significant, risk of VTE.